1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
|
|
- Tracy Lucas
- 5 years ago
- Views:
Transcription
1 COME HOME Non-Hodgkin pathway development worksheet, v6 September Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page Test Name (CT, MRI, KRAS, etc.) CLL/SLL Follicular Marginal Zone s Mantle Cell Diffuse Large B-Cell Burkitt H&P All pts. All pts. All pts. All pts. All pts. All pts. Performance Status All pts. All pts. All pts. All pts. All pts. All pts. B symptoms All pts. All pts. All pts. All pts. All pts. CBC, differential, All pts. All pts. All pts. All pts. All pts. All pts. platelets LDH All pts. All pts. All pts. All pts. All pts. All pts. Comprehensive All pts. All pts. All pts. All pts. All pts. All pts. metabolic panel Hepatitis B testing If using CD20 antibody All pts. If considering rituximab If considering rituximab All pts. All pts. Evaluation of ejection If anthracycline- or anthracenedione-based regimen is indicated fraction Pregnancy test Women of child bearing age Quantitative Optional Optional immunoglobulins Reticulocyte count Optional Diagnostic Chest/ abdominal/pelvic CT Optional All pts. All pts. All pts. All pts. All pts. Beta-2-microglobulin Optional All pts. Optional All pts. Uric Acid Optional Optional Optional All pts. All pts. Bone Marrow Biopsy Optional Stage I-II Gastric: Optional Nongastric: Optional Nodal: Required Splenic: Required All pts. All pts. (> 1.6 cm biopsy) All pts. PET-CT Optional Optional Nongastric: Optional Nodal: Optional Splenic: Optional Optional All pts. Optional FISH Pts with Optional Optional Optional Optional Optional good PS Neck CT Optional Optional Optional Optional 1
2 Test Name (CT, MRI, KRAS, etc.) CLL/SLL Follicular Marginal Zone s SPEP Optional Gastric: Optional Nongastric: Optional Nodal: Optional Splenic: Required Hepatitis C Testing Optional Gastric: Optional Nongastric: Optional Nodal: Optional Splenic: Required H.pylori testing Gastric Endoscopy Gastric: Required Nongastric: Optional Mantle Cell Optional Diffuse Large B-Cell Burkitt MRI Nongastric: Optional Optional Brain MRI Optional Cryoglobulins Splenic: Optional Direct Coombs testing Splenic: Optional Colonoscopy Optional Lumbar puncture Blastic variant/cns symptoms Optional All pts. IPI calculation All pts. Head CT Optional HIV test Optional All pts. Flow cytometry of cerebrospinal fluid All pts. 2
3 A new group of lymphomas starts below: Test Name (CT, MRI, KRAS, etc.) H&P Primary Cutaneous B- Cell All pts.: incl. skin exam Peripheral T-Cell All pts.: incl. skin exam Adult T-Cell Leukemia/ All pts.: incl. skin exam T-Cell Prolymphocytic Leukemia All pts.: incl. skin exam 3 Hairy Cell Leukemia All pts. Performance Status All pts. All pts. All pts. All pts. All pts. B symptoms All pts. CBC, differential, All pts. All pts. All pts. All pts. platelets LDH All pts. All pts. All pts. All pts. All pts. Comprehensive All pts. All pts. metabolic panel Hepatitis B testing If rituximab considered If rituximab considered Evaluation of ejection If anthracycline- or anthracenedione-based regimen is indicated fraction Pregnancy test Women of child bearing age Quantitative immunoglobulins Optional PCMZL Reticulocyte count Diagnostic Chest/ abdominal/pelvic CT All pts. And/or PET- CT, All pts All pts. All pts. Optional Beta-2-microglobulin Uric Acid All pts. Bone Marrow Biopsy Required if PC-DLBCL, Leg type, Optional otherwise All pts. Optional All pts. PET-CT Optional And/or Dx Optional Optional CT, All pts. FISH Optional Optional Optional Optional Optional Peripheral blood flow If CBC cytometry demonstrates lymphocytosis SPEP Optional PCMZL Calculation of IPI All pts.
4 Test Name (CT, MRI, KRAS, etc.) Primary Cutaneous B- Cell Peripheral T-Cell Neck CT Optional Head CT Optional Head MRI Optional Skin biopsy Optional HIV Test Optional Electrolytes, BUN, creatinine, serum calcium Adult T-Cell Leukemia/ All pts. T-Cell Prolymphocytic Leukemia All pts., calcium not required Upper GI endoscopy Optional Skeletal Survey Optional Stool examination for Optional parasites CNS evaluation by CT, Optional MRI or LP HTLV-1 serology Optional Screen for active infections and CMV serology Peripheral blood examination If alemtuzumab is considered Hairy Cell Leukemia Optional 4
5 Mantle Cell Stage I-II 5
6 Mantle Cell Stage IIx, III, IV Yes High-dose therapy with autologous stem cell rescue RT and or any of the regimens below R-HyperCVAD NORDIC Complete Response Candidate for HDT/ASCR? No Treated with RCHOP Yes No Rituximab maintenance Follow Up Relapse Mantle Cell Stage Iix, III, IV CALGB Sequential RCHOP/RICE Alternating RCHOP/RDHAP Bendamustine + rituximab Cladribine + rituximab CVP + rituximab Dose-adjusted EPOCH + rituximab RCHOP Partial Response RT Bendamustine +/- rituximab Bortezomib +/- rituximab Cladribine + rituximab FC FCMR FMR Lenalidomide +/- rituximab PCR PEPC +/- rituximab CR/ Improved PR No further response RT Bendamustine +/- rituximab Bortezomib +/- rituximab Cladribine + rituximab FC FCMR FMR Lenalidomide +/- rituximab PCR PEPC +/- rituximab Ibrutinib Progression 6
7 Diffuse Large B-Cell Stage I-II Note: These guidelines may also be used for AIDS related B Cell, in conjunction with HART. 7
8 Diffuse Large B-Cell Stage III-IV 8
9 Diffuse Large B-Cell Relapse/refractory Disease 9
10 Burkitt 10
11 Chronic Lymphocytic Leukemia - CLL/ Small Lymphocytic - SLL Part 1 11
12 Chronic Lymphocytic Leukemia CLL/ Small Lymphocytic SLL Part 2 12
13 Follicular Stage I, II (initial therapy) 13
14 Follicular Stage II, III, IV (initial therapy) 14
15 Follicular Transformation Histologic transformation to diffuse B-cell lymphoma Clinical Trial Radioimmunotherapy Multiple prior therapies RCHOP Dose-dense RCHOP 14 Dose-adjusted EPOCH RCEPP RCDOP Responsive Disease Consider high dose therapy with autologous stem cell rescue or allogeneic stem cell transplant RCNOP RCEOP IFRT Histologic transformatoin to diffuse large B-cell lymphoma Best Supportive Care Clinical Trial CR Observe RCHOP Dose-dense RCHOP 14 Consider high dose therapy with autologous stem cell rescue or allogeneic stem cell transplant Minimal or no prior chemotherapy Dose-adjusted EPOCH RCEPP RCDOP PR Clinical Trial Consider radioimmunotherapy RCNOP RCEOP Consider high dose therapy with autologous stem cell rescue or allogeneic stem cell transplant Clinical Trial NR Radioimmunotherapy Best supportive care 15
16 Non-gastric MALT 16
17 Splenic MALT If Hepatitis C positive, and no contraindications to treatment, treat Hepatitis C as appropriate If lymphoma progresses, treat per guidelines for Follicular 17
18 Primary Cutaneous B Cell Marginal zone or follicle type 18
19 Primary Cutaneous Diffuse Large B Cell leg type 19
20 Peripheral T-Cell Initial Therapy Multi-agent Chemotherapy Options: CHOP-14 CHOP-21 CHOEP-21 CHOP followed by ICE CHOP followed by IVE alternating with intermediate-dose methotrexate Dose-adjusted EPOCH HyperCVAD alternating with high-dose methotrexate and cytarabine 20
21 Peripheral T-Cell Relapse/Refractory 21
22 Adult T-Cell Leukemia/ 22
23 T-Cell Prolymphocytic Leukemia Hairy Cell Leukemia 23
Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02.01.17 Last Review Date: 11.18 Coding Implications Revision Log Line of Business: Medicaid, HIM-Medical Benefit See Important
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) FOLL-B category designation for first-line therapy options for FL: Bendamustine + rituximab RCHOP RCVP Submission from Genentech to review the data related to obinutuzumab for
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1090-7 Program Prior Authorization/Notification Medication Revlimid (lenalidomide) P&T Approval Date 6/2009, 3/2010, 6/2010, 9/2010,
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Indolent lymphoma
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Indolent lymphoma AA Cancer Centre All patients with a potential or confirmed lymphoproliferative
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationChange Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
More informationLymphoma John P. Leonard, M.D.
Lymphoma 2017 John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department of Medicine Disclosures Consulting
More informationClinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:
Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationInvestigation and Management of Chronic Lymphocytic Leukemia. James Johnston
Investigation and Management of Chronic Lymphocytic Leukemia James Johnston Site Specific Clinics CLL Clinic (787-4454) Erin Elphee BN James Johnston Rajat Kumar Matt Seftel (transplant) Myeloma Clinic
More informationC r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S
1 Christopher R. Flowers, MD, MS Associate Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia 2 1 Anyone can get blood cancer One
More informationClinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Zydelig) Reference Number: CP.CPA.278 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lympoma Non-Hodgkin s Lymphomas Janet H. Van Cleave MSN, ACNP-CS, CS, AOCN Acute Care Nurse Practitioner The Mount Sinai Medical Center of New York City Doctoral Student, Yale University
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 National Comprehensive Cancer Network, Inc. 2015, All
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationNICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52
Non-Hodgkin s lymphoma: diagnosis and management NICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationTreatment of Waldenström s Macroglobulinemia Mayo Consensus
Treatment of Waldenström s Macroglobulinemia Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Mayo Clinic
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationHigh Grade Lymphoma. Trial name & Treatment Key entry criteria Open Sites. Relapsed/Refractory
DISEASE or High Grade Lymphoma DLBCL INCA = Inotuzumab Ozogamicin (INO) + Rituximab + CVP v Gemcitabine + Rituximab + CVP following a steroid pre-phase of pred 60mg x 7 days Second Line Trial name & Treatment
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)
More informationRituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)
Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationClinical Policy: Obinutuzumab (Gazyva) Reference Number: CP.PHAR.305 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationRituxan. Rituxan (rituximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.10 Subject: Rituxan Page: 1 of 8 Last Review Date: June 22, 2017 Rituxan Description Rituxan (rituximab)
More informationRituxan. Rituxan (rituximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.10 Subject: Rituxan Page: 1 of 9 Last Review Date: December 3, 2015 Rituxan Description Rituxan (rituximab)
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationGazyva (obinutuzumab)
Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationRituxan. Rituxan (rituximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.10 Subject: Rituxan Page: 1 of 9 Last Review Date: September 20, 2018 Rituxan Description Rituxan
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
Page 1 Rituximab INITIAL APPLICATION - Post-transplant The patient has B-cell post-transplant lymphoproliferative disder* To be used f a maximum of 8 treatment cycles Indications marked with * are Unapproved
More informationHIV ASSOCIATED LYMPHOMA. Dr N Rapiti
HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2018 Zydelig Description Zydelig (idelalisib)
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationPeripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationClinical Policy: Ibrutinib (Imbruvica) Reference Number: ERX.SPA.08 Effective Date:
Clinical Policy: (Imbruvica) Reference Number: ERX.SPA.08 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationLymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.
Scan for mobile link. Lymphoma Lymphoma is a cancer that develops in the white blood cells of the lymphatic system. Symptoms may include enlarged lymph nodes, unexplained weight loss, fatigue, night sweats
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationPalliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma
Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for low grade lymphoma and Hairy Cell leukemia used in the palliative
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2017 Zydelig Description Zydelig (idelalisib)
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationLymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationCLL13 trial of the GCLLSG/ The GAIA Trial Page 23 of 113 IV. Baseline assessments at screening (for all patients)
CLL13 trial of the GCLLSG/ The GAIA Trial Page 23 of 113 IV. Baseline assessments at screening (for all patients) Informed consent Inclusion-/Exclusion Criteria CIRS Score /Medical history ECOG /Disease-related
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationRituxan (rituximab) DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION Rituxan (rituximab) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationWORKUP. USEFUL IN SELECTED CASES: PET-CT scan Bone marrow biopsy
DIAGNOSIS a WORKUP ESSENTIAL: Review of all slides with at least one paraffin lock representative of the tum should e done y a pathologist with expertise in the diagnosis of primary cutaneous B-cell lymphoma.
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.47 Subject: Revlimid Page: 1 of 7 Last Review Date: September 15, 2016 Revlimid Description Revlimid
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More information